Provided by Tiger Fintech (Singapore) Pte. Ltd.

Veru Inc.

0.5700
-0.0100-1.72%
Post-market: 0.58520.0152+2.67%19:21 EDT
Volume:778.63K
Turnover:449.75K
Market Cap:83.55M
PE:-2.30
High:0.5895
Open:0.5800
Low:0.5692
Close:0.5800
Loading ...

Veru to Participate in the 2025 BTIG Virtual Biotech Conference

GlobeNewswire
·
Yesterday

Veru Inc. Unveils Presentation on Cardiometabolic Drug Pipeline Focusing on Obesity and Atherosclerosis

Reuters
·
09 Jul

BRIEF-Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study

Reuters
·
24 Jun

Veru Reports Positive Results From Phase 2B Quality and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation

THOMSON REUTERS
·
24 Jun

Veru Inc - Enobosarm Shows 93% Greater Fat Loss, 100% Lean Mass Preservation

THOMSON REUTERS
·
24 Jun

Veru Inc - Enobosarm Monotherapy Shows Positive Safety Profile With No Gi Side Effects

THOMSON REUTERS
·
24 Jun

Veru Inc - Granted FDA Meeting to Discuss Phase 3 Clinical Program

THOMSON REUTERS
·
24 Jun

Veru Inc - Enobosarm 3Mg Reduces Weight Regain by 46% After Semaglutide Discontinuation

THOMSON REUTERS
·
24 Jun

Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says

Reuters
·
21 Jun

Trump Says Pharma Tariffs Coming Very Soon

Reuters
·
17 Jun

BRIEF-Veru Reports Positive Safety Results From Phase 2B Quality Study

Reuters
·
28 May

BUZZ-U.S. STOCKS ON THE MOVE-Veru, GameStop, Azul

Reuters
·
28 May

BUZZ-Veru rises as combo drug shows fewer side effects than semaglutide alone in trial

Reuters
·
28 May

Veru Reports Positive Safety Results From Phase 2B Quality Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone

THOMSON REUTERS
·
28 May

Veru Inc - Requests End of Phase 2 Meeting With FDA for Phase 3 Regulatory Clarity

THOMSON REUTERS
·
28 May

Veru Inc: Trial Met Its Prespecified Primary Endpoint

THOMSON REUTERS
·
28 May

Veru Inc - Topline Data for Phase 2B Extension Study Expected in Second Quarter

THOMSON REUTERS
·
28 May

Vaccine Stocks Surge with Moderna up 11%

Tiger Newspress
·
20 May

Trump Says He Will Cut Drug Prices by 59%

Reuters
·
12 May

Veru Inc. Reports Progress in Clinical Trials and Financials

TIPRANKS
·
09 May